Summary
Updated Aug 30, 2026
J. Kevin Buchi is Director of Amneal Pharmaceuticals, Inc. (AMRX). 6 SEC Form 4 filings on record going back to 2024, most recently on 13 August 2026.
Recent Transactions
4Every recent SEC Form 4 transaction J. Kevin Buchi has reported, most recent first.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies J. Kevin Buchi files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- SUVRETTA CAPITAL MANAGEMENT, LLC - $22.44M of BNTC open-market activity in the last 12 months
- Nikita Shah - $4.14M of AMRX open-market activity in the last 12 months
- Jason B. Daly - $3.77M of AMRX open-market activity in the last 12 months
- John Kiely - $882K of AMRX open-market activity in the last 12 months
- Ted C. Nark - $586K of AMRX open-market activity in the last 12 months
- Deborah M. Autor - $451K of AMRX open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is J. Kevin Buchi?
J. Kevin Buchi is a corporate insider, tracked as Director of Amneal Pharmaceuticals, Inc. (AMRX). InsiderAlpha holds 6 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has J. Kevin Buchi submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Where can I see all of J. Kevin Buchi's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow J. Kevin Buchi and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
